BioMarin: cross-border access for the specialty portfolio

Quick orientation

BioMarin Pharmaceutical Inc. is a US-headquartered biotechnology company based in Novato, California. BioMarin operates exclusively in genetic and rare-disease therapeutics. The specialty footprint is anchored in the achondroplasia franchise (Voxzogo), the mucopolysaccharidoses (Vimizim for MPS-IVA, Naglazyme for MPS-VI, Aldurazyme for MPS-I co-marketed with Sanofi Genzyme, Brineura for CLN2-Batten disease), phenylketonuria (Kuvan, Palynziq), hemophilia A gene therapy (Roctavian), and the orphan-disease enzyme replacement franchise.

For Reserve Meds cross-border named-patient programs, the BioMarin portfolio is structurally one of the highest-cross-border-demand catalogs because every product is for an ultra-rare disease where local registration is the exception.

Portfolio in cross-border NPP scope

Voxzogo (vosoritide)

C-type natriuretic peptide analog approved for achondroplasia in patients with open epiphyses (age 5 and older originally; pediatric and adult expansion has occurred). US WAC at standard daily subcutaneous dosing runs into the multi-hundred-thousand-dollar-per-year range. Cross-border requests cluster around pediatric achondroplasia patients in MENA and India where the diagnosis is genetically confirmed but no on-label disease-modifying therapy is locally available.

Vimizim (elosulfase alfa)

N-acetylgalactosamine-6-sulfatase enzyme replacement therapy for mucopolysaccharidosis type IVA (Morquio A syndrome). International requests come from MPS-IVA pediatric and adult patients in MENA and India where consanguinity-driven prevalence is meaningful.

Naglazyme (galsulfase)

N-acetylgalactosamine-4-sulfatase enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Cross-border requests come from MPS-VI patients in MENA and India.

Aldurazyme (laronidase, co-marketed with Sanofi Genzyme)

Alpha-L-iduronidase enzyme replacement therapy for mucopolysaccharidosis type I (Hurler, Hurler-Scheie, and Scheie syndromes). International requests come from MPS-I patients in MENA and India where the disease is recognized and ERT is the only disease-modifying option outside hematopoietic stem cell transplant.

Brineura (cerliponase alfa)

Tripeptidyl peptidase 1 enzyme replacement therapy approved for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease). Administered as direct intracerebroventricular infusion via implanted reservoir. Reserve Meds works case-by-case with the destination pediatric neurosurgery center.

Palynziq (pegvaliase)

Recombinant phenylalanine ammonia lyase enzyme substitution therapy approved for adults with PKU and blood phenylalanine concentrations above 600 micromol/L. International requests come from adult PKU patients in MENA and India whose dietary management has failed.

Kuvan (sapropterin dihydrochloride)

BH4 cofactor for tetrahydrobiopterin-responsive phenylketonuria. International requests come from BH4-responsive PKU patients across pediatric and adult populations.

Roctavian (valoctocogene roxaparvovec)

AAV5-based gene therapy approved for severe hemophilia A in adults with no history of factor VIII inhibitors and no detectable AAV5 antibodies. Reserve Meds coordinates Roctavian on a case-by-case basis because the single-infusion gene therapy is administered at a US-authorized treatment center.

Voranigo (vorasidenib)

Brain-penetrant dual IDH1 and IDH2 inhibitor approved for grade 2 IDH-mutant glioma after surgery. International requests come from IDH-mutant glioma patients in MENA and India.

Why patients route BioMarin products through cross-border NPP

The BioMarin cross-border driver is structural: every product serves a population too small to justify local commercial registration in many MENA and India markets. Achondroplasia, MPS-I, MPS-IVA, MPS-VI, CLN2 Batten, PKU, and severe hemophilia A gene therapy are all populations where cross-border NPP is the default access route. The BioMarin RareConnections patient support program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates BioMarin-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized BioMarin distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For BioMarin market access teams: Reserve Meds maintains structured demand visibility across achondroplasia, MPS, PKU, and gene-therapy franchises. If your group is sizing pre-registration or cross-border supplemental demand in MENA and India, we are open to a structured conversation under NDA.

Common cross-border destinations for the BioMarin portfolio

The achondroplasia franchise (Voxzogo) concentrates in pediatric endocrinology and genetics centers in the UAE, Saudi Arabia, India, and Egypt. The MPS franchise serves tertiary metabolic centers across MENA where consanguinity-driven MPS registries are largest. The PKU franchise tracks metabolic centers in India, Egypt, and the Gulf. Roctavian medical-travel originates from hemophilia A centers in Saudi Arabia, the UAE, and India.

What Reserve Meds provides

For every BioMarin product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a BioMarin product and want a firm quote can start a request below.

Start a request for a BioMarin product

Next step for BioMarin teams

If you are on the BioMarin access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.